Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN ‐ DU Cohort
Authors' conclusion
Early start of biologic therapies in patients with JIA was associated with a higher proportion of patients reaching inactive arthritis within six months, suggesting a window of opportunity to control disease activity.
Study context
- Population
- Biologic-naive patients with nonsystemic juvenile idiopathic arthritis (JIA) at start of biologic therapy, UCAN CAN-DU cohort, Canada and the Netherlands (66% female; median age at symptom onset 11.0 years)
- Participants
- 130 patients
- Exposure
- Early vs intermediate vs late start of biologic therapy after symptom onset
- Earlyn = 35
- Intermediaten = 46
- Laten = 49reference
- Outcome
- Inactive arthritis
- Follow-up
- Six months
Methodological detailsnested cohort, multicentre (Canada and the Netherlands), logistic regression adjusted for active joint count and physician global assessment
- Nested cohort
- Multicentre (Canada and the Netherlands)
- Logistic regression adjusted for active joint count and physician global assessment
Main finding
As reported in the abstract
Significantly higher in early starters
- Adjusted odds of active arthritis after six months, per month of delay to biologic start
- 1.09 (interquartile range: 1.02-1.17, P = 0.009)
Observational data: associations, not effects.
Original publication
Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN ‐ DU Cohort. Arthritis Rheumatol. Published 16 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →